The rapid spread of Alzheimer's disease and the ineffectiveness of treatments pose threats to the world healthcare system. By 2050, it is predicted that the prevalence of this condition will quadruple, placing enormous economic strain on the global medical industry. Therefore, a radical shift in current methods of illness prevention, treatment, and diagnosis is urgently required. With its personalised approach to disease treatment, precision medicine takes into account a patient's unique genetic, environmental, and lifestyle characteristics to help create medicines that are specifically suited to them. Personalised models and clinical medicine are being integrated more easily thanks to the launch of global precision medicine initiatives. The goal of the review is to give a thorough understanding of the neuroin flammatory mechanisms that lead to AD. A succinct summary of the treatments for the condition. The role of precision medicine in AD, which includes genetic perspectives, the use of personalised medicine, and the optimisation of clinical trials with the 3 R's, is then discussed. By demonstrating an in-depth understanding of this novel approach in various facets of the healthcare industry, it enables AD researchers around the world to identify appropriate therapeutic regimens in clinically and pathologically complex diseases like AD. Alzheimer's disease, the most prevalent form of neurodegenerative dementia, affects 17% of Americans and is currently estimated to cost US$236 billion annually. By 2050, the prevalence and cost of diseases are predicted to increase significantly, posing a serious threat to the world's population.
Share this article